Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920729 | 0.90 | TP53 (0.43) | HDAC4SMN1; SMN2TP53HCRTR2 | |
| SCHEMBL3241787 | 0.84 | TP53 (0.44) | HCAR2ALDH1A1ALOX15GAATP53 | |
| SCHEMBL24732163 | 0.82 | MTNR1A (0.44) | SMN1; SMN2 | |
| SCHEMBL3235237 | 0.80 | KMT2A (0.47) | — | |
| SCHEMBL13225531 | 0.79 | HCAR2 (0.41) | HCAR2ALDH1A1TP53HCRTR2 | |
| SCHEMBL13920760 | 0.78 | HCRTR2 (0.37) | HCRTR2 | |
| SCHEMBL23481545 | 0.76 | ALDH1A1 (0.40) | HDAC4SMN1; SMN2ALDH1A1ALOX15PKM | |
| SCHEMBL23409359 | 0.76 | PDE5A (0.34) | TSHR | |
| SCHEMBL29903199 | 0.76 | PDE5A (0.34) | TSHR | |
| SCHEMBL3235203 | 0.75 | KDM4E (0.44) | SMN1; SMN2ALDH1A1DRD4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038087-B2 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | HDAC4 1093/4885SMN1; SMN2 4113/4885HCAR2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.